Do we need still more trials on T4 and T3 combination therapy in hypothyroidism?
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine replacement. It is unlikely that slight over- or under-treatment with thyroxine (T 4) explains remaining complaints. Meta-analysis of randomized clinical trials shows no advantage of T 4/tri-iodothyronine (T 3) combination therapy over T 4 monotherapy. However, each of these trials can be criticized, and none is perfect: most of them failed to mimic the physiological ratio of serum free T 4 (FT 4) to free T 3 (FT 3) concentrations. Development of a sustained-release T 3 preparation given as a single nighttime dose (together with levothyroxine once daily) might maintain physiological serum FT 4–FT 3 ratio's throughout 24 h. Genetic polymorphisms in deiodinase 2 and thyroid hormone transporters have been associated with well-being, fatigue, depression, and greater improvement on combination therapy. Future trials should target carriers of these polymorphisms to see whether they do better on T 4/T 3 combination therapy than on T 4 monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686 · cited 1×
“Could it be that we are slightlyover- or under-treating patients with T4 in view of the marked inter-individual variation in the set point of the hypothalamus‐ pituitary‐thyroid axis ( 20 )? This has been investigated in a double-blind randomized study with a crossover design, in which T4-replaced patients were asked…”
BackgroundSaravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“Six studies in the meta-analysis had a crossover study design ( 5 , 6, 7, 10, 12, 13), and five studies had a parallel study design (8, 9, 11, 14, 15).”
BackgroundResultFish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Wekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299 · cited 1×
“A Dutch study reports impaired cognitive functioning in T4-replaced hypothyroid patients relative to a reference population, as evident from worse scores on tests of cognitive motor speed, attention span, and learning and memory tasks ( 3 ).”
BackgroundSelf-citationGrozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296
Russell, W., Harrison, R. F., Smith, N., Darzy, K., Shalet, S., Weetman, A. P., & Ross, R. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2674 · Cited by 219 · cited 1×
“Serum FT3 has ‐ in contrast to FT4 ‐a circadian rhythm; the FT3 acrophase occurs in early morning hours around 0300 h, w90 min after the TSH acrophase ( 24 ).”
BackgroundTriiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216 · cited 1×
“Could it be that the T3 level of a patient on T4 treatment is in the normal range but differs from the T3 level the patient had prior to the illness? This issue has been clarified in a recent study by Jonklaas et al. ( 19 ).”
Result
Cited by
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Self-citationCombination Treatment with T4 and T3: Toward Personalized Replacement Therapy in Hypothyroidism?
Biondi, B., & Wartofsky, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3399 · Cited by 124
Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism
Wiersinga, W. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.258 · Cited by 114
Fadeyev, V. V., Morgunova, T. B., Melnichenko, G. A., & Dedov, I. I. (2010) · Hormones · doi:10.14310/horm.2002.1274 · Cited by 77
Printing T3 and T4 oral drug combinations as a novel strategy for hypothyroidism
Alomari, M., Vuddanda, P. R., Trenfield, S. J., Dodoo, C. C., Velaga, S., Basit, A. W., & Gaisford, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.062 · Cited by 77
Metadata
- Authors
- Wiersinga, W. M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12
- Volume
- 161
- Issue
- 6
- Pages
- 955-959
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2134537896
- Cited by
- 45
- References
- 27
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? https://app.cochat.ai/papers/10.1530/eje-09-0879
- The paper
- Wiersinga, W. M. (2009). Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? European Journal of Endocrinology. https://doi.org/10.1530/eje-09-0879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.